KRAS and colorectal carcinoma: The safety and efficacy of SOX+B-mab and SOX+C-mab for wild-type KRAS, recurrent advanced CRC as a first-line chemotherapy were almost the same, but they tended to be better in the SOX+B-mab group than in the SOX+C-mab group.